-
Posted by
Two Blokes May 6 -
Filed in
Stock
-
6 views
May 6, 2025 Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasing Comparable order intake increased 2% despite China decline Income from operations increased to EUR 154 million Adjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasing Free cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips Respironics recall-related medical monitoring and personal injury settlements in US Updated full year 2025 outlook for Adjusted EBITA margin and free cash flow; sales outlook remains unchanged Roy Jakobs, CEO of Royal Philips: “We remain dedicated to serving our customers, driving profitable growth and delivering better care for more people. Our order intake growth continued with strong momentum particularly in the US, coupled with positive growth in personal health, providing an encouraging start to the year.
